Worst performer this week was N4P:N4 Pharma which dropped 13% and lost all of last week's 12% gain plus a bit more. I think this will continue to be very volatile.
IQE:IQE had a bad week, and shorters seem to have a grip of it again. The price dropped 9% and is now 24% down on my purchase price. After making over £10K with my original holdings, I can't really complain.
SBTX:SkinBioTherapeutics makes me really mad I didn't take that 18.5p sell opportunity as it dropped another 7% and is now at 14.5p and only 2% up, wiping out all my paper profits. I can afford to trade this one, as I know I'll soon get a huge stash couresty of OPTI:Optibiotix, but I missed my chance in this cycle of the trading peaks and troughs.
KIBO:Kibo Mining is really suffering from the lack of a Power Purchase Agreement. I didn't think it would go below 5p again, but it has, and a 6% drop this week took it to 4.25p. That's 39% down on my purchase price.
There was very little good news this week, and Share of the Week was really tricky to find.
OPTI:Optibiotix climbed 1p which is only 2%. That's worth £746 for me now, so is very welcome, and it was almost enough to earn Share of the Week.
The accolade goes to BLU:Blue Star Capital which climbed a mighty 3% and easily beat everything else in the portfolio. Unfortunately my stake is so small it was worth about £5, but I won't deny it the prize for that.
Big spike in cost as I re-invested my VRS:Versarien proceeds in OPTI:Optibiotix, but as that was at 66p and the bid price is still 65p, there's no real benefit yet. The gap is now very, very wide, but the trend line is still pointing upwards.
The ISA and share portfolios look like this
| Weekly Change | |||
| Cash | £600.14 | +£592.76 | |
| Portfolio cost | £55,460.60 | +£3,224.54 | |
| Portfolio sell value (bid price - commission) | £47,162.70 | (-15%) | -£3,572.31 |
| Potential profits | £39.02 | -£3,467.56 | |
| Yr 3 Dividends | £44.15 | +£0 | |
| Yr 3 Profit from sales | £11,984.62 | +£3,597.31 | |
| Yr 3 Average monthly cash profit | £1,129.61 | (24.4%) | +£321.30 |
| Total Dividends | £1,223.20 | +£0 | |
| Total Profit from sales | £18,697.12 | +£3,597.31 | |
| Average monthly cash profit | £571.35 | (12.4%) | +£100.79 |
| (Sold stocks profit + Dividends - Fees / Months) |
Cash increased as I added £220 for the TLOU:Tlou Energy open offer before I knew I would sell VRS:Versarien. The rest of the cash is left over from the sale. The sale gave me £3,597 profit and most of that was re-invested so the cost rose by £3,224. The value dropped by £3,572, which is in reality around £350 if you don't include the virtual loss from the cashing in of profit. Potential profits were hammered to only £39 which is truly awful, with only SBTX:SkinBioTherapeutics in profit now.
The good news is that actual, real performance is looking amazing. With only 6 weeks to go, my year 3 performance is averaging over £1,000 a month and can only drop to £999 a month by the end of the year unless I sell something at a loss. That's 21% and double my target. My long term average increased by £100 a month over nearly 3 years. At 12.4% I'm comfortably over target - and that was a very ambitious target. I just have to try and cast out of my mind the fact the portfolio is 15% down on paper. That would be turned around in short order by a 10p rise in OPTI:Optibiotix.
I've been under water for a long time now and the trend line is still downwards, but when I see a big spike in portfolio cost it always makes me feel good!
The SIPP looks like this after week 134
| Weekly Change | |||
| Cash | £30.28 | +£0 | |
| Portfolio cost | £27,893.76 | +£0 | |
| Portfolio sell value (bid price - commission) | £27,656.77 | (-0.8%) | -£346.35 |
| Potential profits | £1,832.71 | -£325.30 | |
| Yr 3 Dividends | £292.57 | +£0 | |
| Yr 3 Profit from sales | £1,619.73 | +£0 | |
| Yr 3 Average monthly cash profit | £265.63 | (11.4%) | -£9.16 |
| Total Dividends | £1,208.67 | +£0 | |
| Total Profit from sales | £10,544.92 | +£0 | |
| Average monthly cash profit | £372.94 | (16%) | -£2.81 |
| (Sold stocks profit + Dividends - Fees / Months) |
Not much happening. CAML:Central Asia Metals dropped another 4% which caused most of the fall in potential profits. The 1p rise in OPTI:Optibiotix almost negated the 9% drop in IQE:IQE.
Just slipped into the red again, but the trend line is pointing comfortably upwards. I guess it will become much more shallow as the lows from last summer nudge off the left of the chart.
The open offer for TLOU:Tlou Energy became available yesterday. I was entitled to 3,498 shares based on one share for every six I own, but am feeling optimistic so applied for 10,200 as I have some extra cash from the VRS:Versarien sale. That would take my holding to 31,191 with the new shares almost half the price of my original purchase, and that was almost half what they were trading a few months before. I'm pretty comfortable we'll be back at the 16p range in the next 6 months, which will give me a great return. The only problem is that lots of other TLOU:Tlou Energy holders may be thinking the same thing, so I might only end up with my original allocation.
I'm not expecting anything else of interest next week. As usual I could do with OPTI:Optibiotix breaking out of the 60p range into the 70p range, I need VRS:Versarien to hold off on any news and slip below 100p so I can get back in, I need CAML:Central Asia Metals to shake off this poor spell, I need the gold price to go up, and when are KIBO:Kibo Mining going to sign this bloody PPA?
No comments:
Post a Comment